• Cenicriviroc is a novel dual CCR2 and CCR5
antagonist, and is hypothesised to have both antiretroviral 4 and anti-inflammatory activity 5 • Thus, cenicriviroc is a potential adjunctive therapy to cART for the management of HIV-associated cognitive impairment
• To determine cerebrospinal fluid exposure of cenicriviroc in people living with HIV (PLWH) with symptomatic cognitive impairment
• Assessment of safety, tolerability and cerebral function parameters
• Phase II, open label descriptive study assessing the effects of eight weeks cART intensification with cenicriviroc
• Inclusion criteria: HIV-positive patients suppressed on cART with symptomatic cognitive impairment
• Exclusion criteria: Pre-existing neurological or significant psychiatric comorbidities and those on current or previous CCR5 inhibitors
• Cognitive testing was performed at baseline and week 8 (CogState TM battery), which included a detailed assessment of 7 cognitive domains
• Following cerebral magnetic resonance imaging, lumbar puncture was performed at baseline and week 8, with paired plasma sampling
• Cenicriviroc concentration was determined using a reverse phase highperformance liquid chromatography (HPLC) & mass spectrometry
• EC 90 for cenicriviroc is 0.17 ng/mL, and LLQ for cerebrospinal fluid cenicriviroc concentration (0.24ngl/mL) was utilised as target concentration • In HIV-positive subjects on suppressive cART with cognitive impairment, mean cerebrospinal fluid: plasma cenicriviroc concentration ratio was no more than 0.18% and cenicriviroc cerebrospinal fluid exposure was close to the EC 90
• Whether this is sufficient exposure for antiretroviral and anti-inflammatory activity within the central nervous system needs to be determined
• Participant early withdrawal rate in our neurologically symptomatic cohort was higher compared to larger studies assessing cenicriviroc in asymptomatic PLWH
• Participants with detectable cerebrospinal fluid cenicriviroc concentration had higher cerebrospinal fluid: serum albumin ratios, indicating more disruption to the blood-brain barrier integrity
